DABUR India (DABUR) 4QFY21 result was in line with our estimates. Consolidated revenue grew 25% driven by similar levels of volume growth. HPC business continued to witness strong recovery driven by improvement in demand for discretionary products (Gulabari and FEM) and market share gains in all other segments. In Health Care business; (i) DABUR gained market share in Chyawanprash and Honey (ii) NPDs drove revenue growth for OTCs while Ethical segment grew strong double digit led by distribution expansion, visibility initiatives and activations. Food and Beverage business reported strong recovery in beverages while culinary portfolio continues to grow at strong double digit. Raw...